Rabbit Polyclonal TAB1 Antibody

The TAB1 (TGF-β-activated kinase 1-binding protein 1) antibody is a key tool for studying the TAB1 protein, a critical regulator in cellular signaling pathways, particularly the NF-κB and MAPK cascades. TAB1 functions as an adaptor protein that binds to TAK1 (TGF-β-activated kinase 1), forming a complex essential for activating downstream signaling in response to pro-inflammatory cytokines (e.g., TNF-α, IL-1) and stress signals. It facilitates TAK1 autophosphorylation, triggering pathways involved in immunity, inflammation, apoptosis, and cell differentiation. Structurally, TAB1 contains a conserved C-terminal TAK1-binding domain and an N-terminal domain implicated in oligomerization and interactions with other signaling components. Dysregulation of TAB1-TAK1 signaling is linked to diseases such as cancer, autoimmune disorders, and cardiovascular conditions. TAB1 antibodies enable the detection, quantification, and functional analysis of TAB1 in various experimental setups, including Western blotting, immunoprecipitation, and immunofluorescence. They are crucial for exploring TAB1’s post-translational modifications (e.g., phosphorylation), subcellular localization, and pathological roles. Commercial TAB1 antibodies are typically raised in hosts like rabbits or mice, available as monoclonal or polyclonal variants. Specific validation (e.g., knockout controls) is necessary to ensure antibody reliability, as off-target binding can compromise data accuracy. Research using TAB1 antibodies continues to advance understanding of inflammatory diseases and potential therapeutic targets.